• Ultimate DAPT Trial Principal Results - Ticagrelor monotherapy following one month of dual antiplatelet therapy (DAPT) outperforms 12-month DAPT (aspirin and ticagrelor) post PCI for reducing clinically meaningful bleeding

  • May 21 2024
  • Duración: 12 m
  • Podcast

Ultimate DAPT Trial Principal Results - Ticagrelor monotherapy following one month of dual antiplatelet therapy (DAPT) outperforms 12-month DAPT (aspirin and ticagrelor) post PCI for reducing clinically meaningful bleeding  Por  arte de portada

Ultimate DAPT Trial Principal Results - Ticagrelor monotherapy following one month of dual antiplatelet therapy (DAPT) outperforms 12-month DAPT (aspirin and ticagrelor) post PCI for reducing clinically meaningful bleeding

  • Resumen

  • Ticagrelor monotherapy following one month of dual antiplatelet therapy (DAPT) outperforms 12-month DAPT (aspirin and ticagrelor) post PCI for reducing clinically meaningful bleeding with no increased thrombotic risk.

    In this interview, Gregg W Stone MD, FACC and Anthony N. DeMaria MD, MACC discuss principal results from the Ultimate DAPT Trial.

    Subscribe to ACCEL Lite

    Other ACC resources on DAPT and bleeding risk:

    1. One-Month Ticagrelor Monotherapy After PCI in Acute Coronary Syndromes - IVUS-ACS/ULTIMATE-DAPT

    2. Study Suggests Most Patients with Acute Coronary Syndromes Can Safely Stop Aspirin One Month After Percutaneous Coronary Intervention

    3. ACC.24 Presentation Slides | ULTIMATE-DAPT

    Más Menos
activate_primeday_promo_in_buybox_DT

Lo que los oyentes dicen sobre Ultimate DAPT Trial Principal Results - Ticagrelor monotherapy following one month of dual antiplatelet therapy (DAPT) outperforms 12-month DAPT (aspirin and ticagrelor) post PCI for reducing clinically meaningful bleeding

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.